Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03534323 · ClinicalTrials.gov registry record · Phase 1
Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
A Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 7
- Study locations
NCT03534323 is a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 3 states.
The verdict
NCT03534323, a Phase 1 study of Chronic Lymphocytic Leukemia and Richter Syndrome, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 7
- Study locations
Study Summary
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Duvelisib
Study Locations (7)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Berkshire Medical Center - Pittsfield
Florida
- University of Miami- Sylvester Comprehensive Cancer Center - Miami
Maine
- Northern Light Eastern Maine Medical Center - Brewer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03534323
The ClinicalTrials.gov registry entry for NCT03534323 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (70% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03534323 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Florida, Maine.
Frequently Asked Questions
What is clinical trial NCT03534323 about?
NCT03534323 is a clinical study titled "Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS". This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
What is the current status of trial NCT03534323?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2018-07-12. Estimated completion is 2026-07-01.
What conditions does trial NCT03534323 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Richter Syndrome.
What interventions are being tested in trial NCT03534323?
The interventions under investigation include: Venetoclax (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT03534323?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03534323 being conducted?
This trial has 7 study locations across Florida, Maine, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.